Literature DB >> 16847930

Full-dose ifosfamide can be safely administered to outpatients.

Cristina Meazza1, Gianni Bisogno, Michela Casanova, Ilaria Zanetti, Modesto Carli, Andrea Ferrari.   

Abstract

This report compares a traditional full-dose ifosfamide administration modality (24-hr hyperhydration and mesna infusion) with a simplified 9-hr hyperhydration and mesna infusion for use in outpatients. Acute ifosfamide toxicity was the same, suggesting that ifosfamide could be safely administered to outpatients, reducing the currently-recommended prolonged hyperhydration and mesna uroprotection, thus resulting in shorter hospital stays and consequently lower costs. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 16847930     DOI: 10.1002/pbc.20958

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  4 in total

1.  Cost minimization analysis of two treatment regimens for low-risk rhabdomyosarcoma in children: a report from the Children's Oncology Group.

Authors:  Heidi Russell; J Michael Swint; Lincy Lal; Jane Meza; David Walterhouse; Douglas S Hawkins; M Fatih Okcu
Journal:  Pediatr Blood Cancer       Date:  2014-01-22       Impact factor: 3.167

2.  Comparison of Rapid Hydration and Standard Hydration Prior to Ifosfamide Administration in Pediatric Patients: A Safety and Efficacy Study.

Authors:  Aubrie Eaton; Tosha Egelund; John Ng
Journal:  J Pediatr Pharmacol Ther       Date:  2020

3.  Feasibility and safety of outpatient administration of ifosfamide and etoposide for pediatric patients with Ewing sarcoma in a resource-limited setting amid the COVID-19 pandemic.

Authors:  Saliha Sarfraz; Haleema Saeed
Journal:  Pediatr Blood Cancer       Date:  2022-03-02       Impact factor: 3.838

4.  Desmoid fibromatosis in pediatric patients: management based on a retrospective analysis of 59 patients and a review of the literature.

Authors:  Caroline Oudot; Daniel Orbach; Véronique Minard-Colin; Jean Michon; Pierre Mary; Christophe Glorion; Sylvie Helfre; Jean-Louis Habrand; Odile Oberlin
Journal:  Sarcoma       Date:  2012-08-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.